What Everest Medicines Investors Missed Before The Fall
Everest Medicines has been busy signing licensing deals for kidney disease drugs and lining up new autoimmune therapies across Asia Pacific. Investors who held Everest Medicines over the past year are down 42.8%, including dividends. If you had committed fresh capital a year ago, that gap between active dealmaking and a sharply weaker share price would feel hard to reconcile. The key question now is whether the current business mix really supports the expectations analysts had on record at the start.
If the move has made Everest Medicines harder to judge, start where the gap is still open and scan 195 high quality undervalued stocks.
The Two Everest Medicines Stories Investors Had To Weigh
The shares cost HK$49.66 at the start of the period, and anyone looking at Everest Medicines then was really choosing between two very different stories.
On the optimistic side, the bull case pointed to a Fair Value of HK$62.67, a price implied by expectations of 62.3% revenue growth and profit margins reaching 21.2% within three years, helped by broader NEFECON and VELSIPITY uptake.
The bearish script anchored on a Fair Value of HK$25.58 and focused on stricter Chinese pricing and regulatory pressure, along with the risk that heavy reliance on in-licensed drugs and equity funding would keep dilution on the table.
What The Results Changed For Everest Medicines
The licensing of civorebrutinib to Travere and new Asia Pacific rights for DMX-200 and Bejescin kept Everest Medicines closely aligned with the optimistic case that assumed partnerships and portfolio breadth. The H1 2026 report showed revenue of CNY1,147.84m and a much smaller net loss of CNY5.944m, with net margin at -0.5%. Profitability was still not proven, so the evidence cut both ways.
The lesson is simple. When a story relies on margin expansion, track the reported net margin and absolute earnings, not just new deals or pipeline headlines.
What Today’s Everest Medicines Price Is Asking You To Believe
Everest Medicines now trades at HK$27.94. The selected Narrative places its Fair Value above that level and ties the gap to a shift from single-drug hopes to a broader profitability and multi-franchise earnings story across nephrology, cardiovascular disease and mRNA oncology.
For the drop over the past year to look like an opening rather than a warning, a buyer today would need to believe Everest Medicines can turn its renal and cardiovascular portfolios, A2MS network and early mRNA pipeline into sustained, profitable launches across Asia.
"A key requirement is Everest Medicines executing on its plan to turn its growing renal and cardiovascular portfolios, expanding A2MS commercial network, and mRNA oncology programs into sustained product launches and durable hospital coverage across Greater China and wider Asia."
One Narrative disagrees with today's price. → See where this Narrative says Everest Medicines should trade
Another Way Kidney Bets Spread
Everest Medicines is one way to lean into kidney and autoimmune therapies. It is not the only route available to you.
Drug makers chasing similar diseases still need fresh treatments and devices that handle complex conditions over long periods.
One large healthcare group focuses on that need, putting capital into new medicines and high end equipment for serious illnesses.
Its work stretches from cancer and immune disorders to heart rhythm tools and surgical robots that shape how hospitals treat patients.
If kidney and autoimmune bets interest you, that broader engine might deserve a closer look next to Everest Medicines.
The case is on the record, with the assumptions it rests on. → See the Narrative that values this company 20% above its price
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com